logo
Product categories

EbookNice.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link.  https://ebooknice.com/page/post?id=faq


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookNice Team

(Ebook) Melanoma - Biologically targeted Therapeutics (Current Clinical Oncology) by Ernest C. Borden ISBN 9780896038769, 9781592591596, 0896038769, 1592591590

  • SKU: EBN-1770376
Zoomable Image
$ 32 $ 40 (-20%)

Status:

Available

4.4

37 reviews
Instant download (eBook) Melanoma - Biologically targeted Therapeutics (Current Clinical Oncology) after payment.
Authors:Ernest C. Borden
Pages:415 pages.
Year:2002
Editon:1st
Language:english
File Size:9.76 MB
Format:pdf
ISBNS:9780896038769, 9781592591596, 0896038769, 1592591590
Categories: Ebooks

Product desciption

(Ebook) Melanoma - Biologically targeted Therapeutics (Current Clinical Oncology) by Ernest C. Borden ISBN 9780896038769, 9781592591596, 0896038769, 1592591590

Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. The contributors focus on providing the rationale and background for translating the many promising biologically targeted therapies via clinical trials into effective new therapies. Among the interventional agents treated are: cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (Nf-kB and IL-8) for anti-angiogenesis therapies.
*Free conversion of into popular formats such as PDF, DOCX, DOC, AZW, EPUB, and MOBI after payment.

Related Products